ALL Flashcards
Immunophenotype: B-cell
CD19, CD20, CD79a, cytoplasmic CD22, PAX5
CD3- (T-cell)
Myeloid Ag that rules out B-ALL/LBL
MPO
Immunophenotype: Hairy cell leuk
CD11c+, CD103+
Immunophenotype: blasts
CD34+, CD117+, CD123+, HLA-DR+
Immunophenotype: myeloid lineage (AML)
CD13, CD33, MPO, CD11b
Immunophenotype: T-cell
CD2, CD3, CD5, CD7, CD30
Immunophenotype: common leukocyte
CD45
ALL poor risk cytogenetics
hypodiploid
KMT2A rearranged t[4;11]
t(v;14q32)/IgH
t(17;19)
T(9;22)
complex karyotype
BCR-ABL1-like (JAK-STAT, ABL class)
C21 amplification
IKZF1 alterations
Tx: MRD+ following ALL induction?
Blinatumomab followed by HCT
Favorable cytogenetics in ALL?
hyperdiploidy, t(12;21), ETV6-RUNX1
HSCT late phase (>100days) complications?
Aspergillus, PJP, encapsulated bacteria, VZV
HSCT post-engraftment phase (30-100days) complications?
CMV, PJP, aspergillus
HSCT pre-engraftment phase (<30 days) complications?
HSV, G +/- bacteria, candida/aspergillus – from neutropenia
Significant complication of cyclosporine or tacrolimus
TMA (thrombotic microangiopathy) with hemolytic anemia
Stage IV Acute GVHD criteria?
Skin: erythema >50% BSA with bullous/desquamation >5% BSA
Liver: bili>15
Lower GI: severe abdominal pain with or without ileus or grossly bloody stool
Ph-like ALL treatment for ABL1, ABL2, CSF1R and PDGFRB fusions?
dasatinib
ALL with JAK-STAT, ABL fusions, PDGRF, NTRK, FLT3 mutations is called?
Ph-like (BCR-ABL1 like) ALL
MRD level detected by 6-color flow cytometry to predict relapse in ALL after HSCT?
<1 x 10^-4 (threshold for flow) or <0.01%
MRD level detected by PCR/NGS for leukemic cells?
<1 x 10^-6 or <0.0001%
Blinatumumab MOA?
Connector between CD19 on (B-cell leukemic cells) and CD3 (on T-cell lymphocytes)
Tx for ALL relapse in CNS or testes?
systemic therapy (chemo, bilatumomab, inotuzumab ozo, CAR-T with Tisa or Brex)
blackbox warning for inotuzumab ozogamicin?
veno-occlusive liver disease
what is the % of hemosiderin laden macrophages among all alveolar macrophages (from BAL) to help confirm dx of Diffuse Alveolar Hemorrhage (DAH)?
20%
How long do you continue TKI in Ph+ ALL after HSCT?
1 year
Large Granular Lymphocytic (LGL) leukemia is divided into which 2 groups?
- T-cell LGL leukemia
- NK cell LGL leukemia
T-LGL associations?
Rheum arthritis, splenomegaly, anemia, neutropenia
Substitution for pegaspargase in ALL regimens?
can use calaspargase (Cal-PEG) in pt <21yo for mor sustained activity
Risk factor to develop pure red cell aplasia following HSCT?
use of fludarabine/busulfan conditioning regimen
MC mutation in hypodiploid ALL?
TP53
